The US FDA has granted approval for Ferring Pharmaceuticals’ Rebyota to prevent Clostridioides difficile infection recurrence.

Immunoinformatics allows researchers to develop vaccines without microbial culturing, thus saving time and money.

Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).

DelveInsight’s, “Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route […]

MGB-BP-3 is a potential first-in-class antibiotic, a Strathclyde Minor Groove Binder (S-MGB), that has successfully completed Phase IIa clinical trials for the treatment of Clostridioides difficile associated disease. Its precise mechanism of action and the origin of limited activity against …

(Nevada, USA) DelveInsight’s “Clostridium Difficile Infection Market Insight, Epidemiology and Market Forecast – 2032” report provides current treatment practices, emerging drugs, Clostridium Difficile Infection market share of the individual therapies, current and forecasted Clostridium Difficile Infection market size from 2019 to 2032 segmented by seven major markets. The report also offers current Clostridium Difficile […]

The suggested potent targets could act as broad-spectrum drug targets for C. difficile. However, further validation needs to be done before using them for lead compound discovery.

In terms of prophylaxis against C. difficile infection, @bhmullish says some adsorbent agents and vaccines will be worth considering in the future@esnm_eu #GMFHCoverage pic.twitter.com/pZ3e0oQEoz— GutMicrobiota Health (@GMFHx) November 22, 2022

First-line faecal microbiota transplantation is highly effective and superior to the standard of care vancomycin alone in achieving sustained resolution from C. difficile, according to a recent study in @LancetGastroHep now presented by @bhmullish @esnm_eu #GMFHCoverage pic.twitter.com/Ivol77W1XS— GutMicrobiota Health (@GMFHx) November 22, 2022

The loss of gut microbiota-derived bile salt hydrolases predisposes to CDI. @bhmullish & colleagues showed restoration of gut BSH functionality contributes to the efficacy of FMT in treating rCDI based on a paper in @Gut_BMJ @esnm_eu #GMFHCoverage pic.twitter.com/0jeZAkk7Ax— GutMicrobiota Health (@GMFHx) November 22, 2022

Blount: As microbiome is considered a new organ in the scientific and medical arena, there is an ongoing debate on whether fecal microbiota transplant is a drug or an organ@esnm_eu #GMFHCoverage pic.twitter.com/x9UM5e9PdE— GutMicrobiota Health (@GMFHx) November 22, 2022

The design of clinical trials is relevant for ensuring reproducibility of microbiota-based therapeutics. Blount now shares the pipeline of RBX2660 for reducing recurrent C. difficile infection @Rebiotix @FerringMBiome @esnm_eu #GMFHCoverage pic.twitter.com/4QlKcJrYy6— GutMicrobiota Health (@GMFHx) November 22, 2022

According to Blount, microbiome changes are relevant in explaining the efficacy of RBX2660. High engraftment persisted to at least 6 months after study treatment @esnm_eu #GMFHCoverage pic.twitter.com/rX4sRcbZLe— GutMicrobiota Health (@GMFHx) November 22, 2022

An easy-to-administer oral biologic kept repeat C difficile infections at bay in a new study.

Dublin, Nov. 22, 2022 (GLOBE NEWSWIRE) -- The "Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,...

The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

What is the potential of microbiome-based medicine in the era of precision management? This special issue in @AGA_Gastro is still timely and includes interesting readings in the field, such as major caveats in defining a healthy microbiome: https://t.co/PdjimGbLnz pic.twitter.com/zAUPBCD9x4— GutMicrobiota Health (@GMFHx) November 19, 2022

C Difficile Infection Drug Market 2022 Forecast to 2029 research provides accurate economic global and country level predictions and analyses It provides a comprehensive perspective of the competitive market as well as an in depth supply chain analysis to assist ...

SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

The CDi-screen is suitable for studying C. difficile proliferation in a complex gut ecosystem and for screening for anti-pathogenic interventions that target C. difficile directly and/or indirectly through interactions with the gut microbiota. Different doses of compounds such as in th …

/PRNewswire/ -- A new in vitro research study conducted by the Eurofins Labs confirmed efficacy of Doctor's Biome proprietary blend of probiotics (10...

– Investigational oral microbiome therapeutic was observed to reduce recurrent C. difficile infection (rCDI) after just one recurrence and remained low regardless of diagnostic approach –– Clinical data shows SER-109 is well tolerated, including among people with multiple comorbidities –CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeuti..

DBMR team makes use of simple language and easy to understand statistical images to provide thorough information and in-depth data on

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, tod

More than 70% of patients treated with RBX2660 were recurrence free at the 8 week mark.